Showing 1,295 results

Filters Content type: News, Editors' picks, About HIV Topic: New & experimental HIV treatments

News and information about clinical trials and regulatory approval of new medications to treat HIV.

New & experimental HIV treatments

Phase 3 DOR/ISL Shows Promise for HIV Treatment

Editor's pick
Infectious Disease Special Edition
31 December 2025
New & experimental HIV treatments

Gilead’s Investigational Single-Tablet Regimen of Bictegravir and Lenacapavir for HIV Treatment Meets Primary Endpoint in Phase 3 ARTISTRY-2 Trial

Editor's pick
Gilead Sciences press release
16 December 2025
Government, leadership & policy

Top 10 HIV Clinical Developments of 2025

Editor's pick
TheBodyPro
15 December 2025
New & experimental HIV treatments

Lenacapavir drug resistance in phase 1b study

Editor's pick
i-Base
25 November 2025
New & experimental HIV treatments

Merck's HIV combo matches Gilead's Biktarvy in latest phase 3 test for islatravir

Editor's pick
FierceBiotech
22 November 2025
New & experimental HIV treatments

Gilead hails phase 3 victory for single-tablet combo of bictegravir and lenacapavir, preps filings

Editor's pick
FiercePharma
17 November 2025
Antibody-based treatment

Antibody from Tanzanian woman suppresses almost all tested HIV variants including resistant viruses in pre-clinical study

News
10 November 2025
New & experimental HIV treatments

IDWeek 2025: Pirmitegravir demonstrates proof of concept in HIV

Editor's pick
Clinical Trials Arena
30 October 2025
New & experimental HIV treatments

Weekly Oral HIV Treatment Looks Good at Two Years

Editor's pick
POZ
23 October 2025
New & experimental HIV treatments

HIV Maturation Inhibitor Shows Promise in Early Study

Editor's pick
POZ
4 September 2025
New & experimental HIV treatments

Ulonivirine Shows Promise for Weekly Oral HIV Treatment

Editor's pick
POZ
4 August 2025
Antibody-based treatment

Broadly neutralising antibodies plus immune modulator may delay HIV rebound

News
21 July 2025
New & experimental HIV treatments

U.S. FDA Accepts New Drug Application for Merck’s Doravirine/Islatravir, an Investigational, Once-Daily, Oral, Two-Drug Regimen for Treatment of Adults with Virologically Suppressed HIV-1 Infection

Editor's pick
Merck press release
10 July 2025
New & experimental HIV treatments

FDA Pauses Trials of Two Experimental Long-Acting HIV Drugs

Editor's pick
POZ
12 June 2025
New & experimental HIV treatments

ACTG Presents Study at CROI Demonstrating Potential of CMV-specific Antiviral Inhibitor to Improve Aging-Related Outcomes among People Living with HIV and CMV

Editor's pick
GlobeNewswire
18 March 2025
Injectable & long-acting HIV treatment

New long-acting HIV drugs show promising early results

News
17 March 2025
Antibody-based treatment

Broadly neutralising antibody N6LS could be part of long-acting HIV treatment

News
17 March 2025
New & experimental HIV treatments

Studies confirm non-inferiority of doravirine / islatravir to standard HIV treatment

News
17 March 2025
Injectable & long-acting HIV treatment

What do we know about injectable HIV medication?

About HIV
May 2024
Injectable & long-acting HIV treatment

Top 5 stories on injectable HIV treatment and PrEP from CROI 2024

News
25 March 2024
New & experimental HIV treatments

Drug candidate may 'unmask' latent HIV-infected cells, mark them for destruction

Editor's pick
Medical Xpress
20 March 2024
HIV treatment

Top 5 HIV treatment stories from CROI 2024

News
18 March 2024
New & experimental HIV treatments

New Once-Daily HIV Oral Alternative Advances

Editor's pick
Medscape (requires free registration)
9 March 2024
New & experimental HIV treatments

CytoDyn finally clears FDA hold on HIV program after 2 years

Editor's pick
FierceBiotech
8 March 2024